secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2023-10-10T23:59:59+00:00
Accession:  0001193125-23-253493
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana cuts workforce 29%, delays SG299 IND; 2024 cash burn under $200M
---------------------------------------------------------------------

- Workforce reduction of ~29%; expects 2024 operating cash burn below $200 million.
- IND submitted for SC291 (HIP CD19 CAR T) in autoimmune diseases; initial data expected 2024.
- Delaying SG299 (in vivo CAR T) IND; reducing near-term investment in fusogen platform.
- SC262 (HIP CD22 CAR T) IND on track for Q4 2023; proof-of-concept data expected 2024.
- HIP-modified islet cell CTA submitted for type 1 diabetes trial; data expected 2023 and 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000119312523253493/0001193125-23-253493-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000119312523253493/d526014d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-253493

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer